



Coherus BioSciences to Report Second Quarter 2015 Financial Results on August 10

REDWOOD CITY, Calif., July 28, 2015 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), a leading pure-play, global biosimilars company with late-stage clinical products, today announced that it has scheduled a conference call for Monday, August 10, 2015 at 1:30 p.m. PT / 4:30 p.m. ET to discuss its second quarter 2015 financial results and product updates. Participating on the call will be Denny Lanfear, President and Chief Executive Officer, and Jean-Frédéric Viret, Ph.D., Chief Financial Officer. Prepared remarks will be followed by a question and answer session.

Financial results will be released over the wire after market close on Monday, August 10, 2015 and posted at <http://investors.coherus.com>.

Conference Call Information

When: August 10, 2015, 1:30 p.m. PT

Dial-in: (844) 452-6826 (domestic) or (765) 507-2587 (international)

Conference ID: 86021327

Webcast: <http://investors.coherus.com>

Please join the conference call at least 10 minutes early to register.

The webcast of the conference call will be available for replay through August 24, 2015.

About Coherus BioSciences, Inc.

Coherus is a pure-play biosimilar platform company that develops and commercializes high-quality therapeutics for major regulated markets. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. Composed of a team of proven industry veterans with world-class expertise in process science, analytical characterization, protein production and clinical-regulatory development, Coherus is positioned as a leader in the global biosimilar marketplace. Coherus is advancing three late-stage clinical products towards commercialization, CHS-1701 (pegfilgrastim biosimilar), CHS-0214 (etanercept biosimilar) and CHS-1420 (adalimumab biosimilar), as well as developing a robust pipeline of future products. For additional information, please visit www.coherus.com.

CONTACT: Keith Vendola
Investor Relations
Coherus BioSciences, Inc.
kvendola@coherus.com
+1 (650) 437-6239



Coherus BioSciences